Market Access News | pharmaphorum

News

Legislation that would introduce big changes for pharmacy benefit managers (PBMs) is inching closer to realisation in the US Congress.

News

Neurocrine Bioscience's Crenessity is the first new option for classic congenital adrenal hyperplasia (CAH) in more than 70 years.

News

Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label.

News

The money spent by the NHS on newly approved therapies recommended by NICE might have been better spent elsewhere, according to a new study.

News

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement.

News

Readout from NEXUS study sets up mid-2025 refiling for Minoryx and Neuraxpharm's leriglitazone for rare disease cerebral adrenoleukodystrophy (cALD).